Abstract
AbstractSchizophrenic patients taking haloperidol prophylactically were screened for a haloperidol monitoring project at four medical centers. Fifty-five patients participated. Most patients had doses and plasma levels below those found in acute treatment studies; however, a sizeable minority had doses and levels that were greater than was probably needed for prophylaxis. Six percent of patients appeared to be rapid metabolizers. A regression formula was calculated for prediction of haloperidol level from daify dose. There were no apparent differences in dosing practices between two university-affiliated medical centers and two nonaffiliated centers. More research is needed to establish optimal prohylactic haloperidol levels. However, hayoperidol monitoring can provide some assistance for choice of dose.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call